Tripathy D, Sohn J, Im S-A, et al. First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial. SABCS 2017, GS2-05.
Bevolkingsonderzoeken vonden in 2023 bij 27.000 mensen kanker of voorstadia daarvan
nov 2024 | Borstkanker, Gynaecologische oncologie, Maag-darm-leveroncologie